Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

$478 $370 Accrued compensation 601 1,039 Accrued research and development 623 1,067 Other accrued expenses 621 540 Notes payable - current portion 1,982 2,833 ------- ------- Total current liabilities 4,305 5,849 Non-current liabilities: Notes payable - non-current portion -- 191 Deferred rent 367 276 ------- ------- Total non-current liabilities 367 467 Commitments and contingencies Stockholders' equity: Common stock 18 18 Additional paid-in capital 209,877 209,370 Deferred stock-based compensation (1) (2) Accumulated other comprehensive income 9 32 Deficit accumulated during the development stage (194,746) (190,144) -------- -------- Total stockholders' equity 15,157 19,274 ------- ------- Total liabilities and stockholders' equity $19,829 $25,590 ======= ======= (1) The balance sheet at December 31, 2008, has been derived from the audited consolidated financial statements at that date. NeurogesX, Inc. Stephen Ghiglieri Chief Financial Officer (650) 358-3310 The Ruth Group Sara Ephraim (investors) (646)
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... N.M., Dec. 12 Biomoda, Inc. (OTC,Bulletin Board: ... New,Mexico Institute of Mining and Technology (New Mexico ... to collaborate on clinical,studies and the development of ... commercialization of its assay for the early,detection of ...
... mg/Day Dose for PRISTIQ for the ... Treatment of Major Depressive Disorder, COLLEGEVILLE, Pa., ... WYE ), announces that data from,two Phase 3 clinical studies ... patients who received a 50 mg/day dose of PRISTIQ for ...
... expanding pipeline of products to ... treat ophthalmic diseases, ... developing novel therapeutics for the treatment,of ophthalmic diseases announced today ... a strong, international syndicate of new and,existing investors led by ...
Cached Biology Technology:Biomoda Announces Collaborative Agreement With New Mexico Tech 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6Fovea Pharmaceuticals Completes EUR30M Series B Financing 2Fovea Pharmaceuticals Completes EUR30M Series B Financing 3Fovea Pharmaceuticals Completes EUR30M Series B Financing 4
(Date:4/15/2014)... who study the deadliest infectious diseases recognized the contributions ... at the University of Texas Medical Branch, with a ... on Filoviruses. The filoviruses include Ebola and Marburg viruses ... people infected. The current outbreak of Ebola virus raging ... so far. , "This award represents the culmination ...
(Date:4/15/2014)... American Association of Anatomists (AAA) is honored to announce ... presented during the Closing Awards Ceremony being held at ... at 7:30 p.m. during AAA,s 2014 Annual Meeting at ... winners are: , Henry Gray/Elsevier Distinguished Educator ... of Medicine at Mount Sinai, Past-President of the American ...
(Date:4/15/2014)... cause temperatures in the Congo Basin to increase ... caused by greenhouse gases by half, according to ... Leuven, Belgium. , Explosive population growth and inefficient ... rainforests in Central Africa. A team of researchers ... practices will affect longer-term temperatures in the region. ...
Breaking Biology News(10 mins):International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3American Association of Anatomists 2014 award winners 2Study: Deforestation could intensify climate change in Congo Basin by half 2
... and Molecular Biology of Universitat Autnoma de Barcelona ... with a tendency to cause conformational diseases such ... amyloidotic cardiomyopathy, etc. finally end up causing them. ... 3D structure and studied why these proteins finally ...
... protein found present in all cells in the body could ... at the University of Edinburgh have found that the protein ... in lipid droplets the parts of cells used to ... of invadolysin were linked to reduced amounts of fat deposits. ...
... was a frightening failure in drug safety processes. In ... died after being administered contaminated doses of the common ... in China and discovered with the help of scientists ... pure heparin that is was undetectable to all but ...
Cached Biology News:Mechanism related to the onset of various genetic diseases revealed 2Mechanism related to the onset of various genetic diseases revealed 3Rensselaer leads effort to replace 1 of the most widely used drugs in American hospitals 2Rensselaer leads effort to replace 1 of the most widely used drugs in American hospitals 3
Large-capacity refrigerated incubator chamber holds up to 4 independently-operated shakers. Programmable heat, refrigeration, humidifcation are standard. Photosynthetic operation, optional....
...
... and disposable ESI Chip allow users to ... electrospray mass spectrometers for life science applications. ... to either speed analysis for increased throughput ... or long acquisition times for proteomics and ...
... are optimised for SYBR Green I assays and ... PCR, with the exception of template and primers. ... levels of active SYBR Green I dye and ... buffer that enables detection of low copy number ...
Biology Products: